Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: May-03-10
Credit Expiration Date: May-03-11

Faculty

Dea Belazi, PharmD, MPH, RPH, PAHM
AlchemiPharma LLC
Consultant to Pharmaceutical/Health Care Industry
Garnet Valley, Pennsylvania

Mark Molitch, MD
Professor of Medicine
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Gary Owens, MD
President
Gary Owens Associates
Medical Management and Pharmaceutical Consulting
Glen Mills, Pennsylvania

Credit Hours

Physicians CME: 1 credit
Pharmacists CPE: 1 contact hour (0.1 CEU)

Medium

Online Presentation

Program Description

THIS PROGRAM WAS ORIGINALLY PRESENTED AS AN AUDIOCONFERENCE SERIES BEGINNING FEBRUARY 25, 2010. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE AUDIOCONFERENCE, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.

The American Diabetes Association (ADA) estimates that more than 20 million people in the United States—approximately 7 percent of the population—have diabetes, and approximately 57 million more have a condition known as pre-diabetes. One in 3 people born in 2000 will develop the condition at some point in their lifetime. Despite numerous approaches to therapy and a variety of pharmacologic agents at clinicians' disposal, a large proportion of patients do not achieve optimal glycemic control.

Several new classes of agents have the potential to reshape diabetes treatment. For instance, new and emerging therapies have shown promising results in lowering A1C levels without increasing the risk of side effects such as weight gain or hypoglycemia. This program will highlight this new generation of therapies and explore their potential and optimal use in managed care populations. The program will also identify a variety of strategies (including pay for performance, disease management, and quality improvement programs) that managed care professionals can employ to help clinicians overcome the "clinical inertia" associated with type 2 diabetes and alleviate health disparities among vulnerable and/or high-risk patient groups.

Armed with information about the emerging generation of therapies and a commitment to national guidelines and improved patient monitoring, managed care professionals are uniquely positioned to help lessen the public health burden related to the suboptimal management of type 2 diabetes.

Program Developer/Facilitator


.

Target Audience

Managed care medical directors and pharmacy directors, as well as other managed care physicians and pharmacists involved in the care of patients with type 2 diabetes.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Identify strategies within managed care to improve key type 2 diabetes performance gaps.
  2. Describe opportunities to reduce clinical disparities associated with vulnerable patient groups, including wellness initiatives.
  3. Review the pharmacologic properties and clinical data on new and emerging type 2 diabetes therapies.
  4. Compare the efficacy and safety of existing and emerging classes of medications for the management of type 2 diabetes.

Disclosures

It is the policy of the accredited providers to ensure balance, independence, objectivity and scientific rigor in all continuing education programs. Faculty must disclose to program participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation.

Dr. Belazi discloses that he has no current financial relationships with commercial interests and/or the opportunity to affect content relevant to the products or services of those commercial interests.

Dr. Molitch discloses that he has received honoraria for serving as a consultant to Abbott Laboratories, Pfizer Inc., and Sanofi-Aventis; and he has received grant support from Amgen, Eli Lilly and Company, Novo Nordisk, and sanofi-aventis.

Dr. Owens discloses that he has received honoraria for serving as a consultant to Amgen, AstraZeneca, Asthmatx, Biosense Webster, Eli Lilly and Company, Genentech, and Schering-Plough Corporation; has served on the speakers bureau for Genentech; and has conducted market research for AstraZeneca.

Planning committees of NAMCP, ProCE, and Medical Communications Media have no real or perceived conflicts of interest to disclose. Katie Eads, VP Education of NAMCP, has no real or perceived financial relationships to disclose. Joseph Kim, MD, VP of Medical Affairs of Medical Communications Media has no real or perceived conflicts of interest to disclose. Kathleen Hines, Senior Medical Writer/Editor of Medical Affairs of Medical Communications Media has no real or perceived conflicts of interest to disclose.

Please note: The opinions expressed in this program should not be construed as those of the CME/CPE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this program may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental, and participants are advised to consult prescribing information and professional literature.

Credit Statements

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Association of Managed Care Physicians (NAMCP) and Medical Communications Media, Inc. The NAMCP is accredited by the ACCME to provide continuing medical education to physicians.

NAMCP designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists: ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 221-999-10-021-H01-P has been assigned to this knowledge-based home-study web program (initial release date 05-03-10). This program is approved for 1.0 contact hours (0.10 CEUs) in states that recognize ACPE providers.

The program is provided at no cost to participants. Statements of credit will be available immediately online at www.cmecorner.com following completion of the web program or mailed to participants within 6 weeks of program completion if faxed or mailed. Participants must attend the entire program, complete a program evaluation form, and complete a post-test with a score of 70% or higher to receive pharmacy CE credit. No partial credit will be given.

Commercial Support Statements

Supported through an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Certificate Fee

$0.00

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS